If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

Share Price is delayed by 15 minutes
Get Live Data
6.50    -0.20 (-2.99%)
Bid:
6.00
Ask:
7.00
Spread: 1.00 (16.667%)
Market Cap: £411.61m
AGY Live PriceLast checked at - London Stock Exchange

Intraday Allergy Thera. Share Chart

Form 8.5 (EPT/NON-RI)

16 Oct 2023 12:42

RNS Number : 2621Q
Cavendish Securities PLC
16 October 2023
Β 

FORM 8.5 (EPT/NON-RI)

Β 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN

EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)

Rule 8.5 of the Takeover Code (the "Code")

Β 

1. KEY INFORMATION

Β 

(a) Name of exempt principal trader:

Cavendish Securities Plc

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Allergy Therapeutics Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Allergy Therapeutics Plc

(d) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

13/10/2023

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

Β 

2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER

Β 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

Β 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Β 

Class of relevant security:

Β 

Ord 0.1p

Β 

Β 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

41644

Β 

0.01

Β 

Β 

(2) Cash-settled derivatives:

Β 

Β 

Β 

Β 

Β 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

Β 

Β 

Β 

Β 

Β 

TOTAL:

41644

Β 

0.01

Β 

Β 

Β 

All interests and all short positions should be disclosed.

Β 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental FormΒ 8 (Open Positions).

Β 

(b) Rights to subscribe for new securities (including directors' and other employee options)

Β 

Class of relevant security in relation to which subscription right exists:

Β 

Details, including nature of the rights concerned and relevant percentages:

Β 

Β 

Β 

3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

Β 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

Β 

The currency of all prices and other monetary amounts should be stated.

Β 

(a) Purchases and sales

Β 

Class of relevant security

Purchases/ sales

Β 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

Ord 0.1p

Sales

200000

Β 

1.39

1.39

Β 

Β 

(b) Cash-settled derivative transactions

Β 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

Β 

Β 

Β 

(c) Stock-settled derivative transactions (including options)

Β 

(i) Writing, selling, purchasing or varying

Β 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

Β 

(ii) Exercise

Β 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

Β 

Β 

Β 

Β 

Β 

Β 

Β 

(d) Other dealings (including subscribing for new securities)

Β 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

Β 

Β 

Β 

Β 

Β 

Β 

Β 

4. OTHER INFORMATION

Β 

(a) Indemnity and other dealing arrangements

Β 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

Β 

None

Β 

Β 

(b) Agreements, arrangements or understandings relating to options or derivatives

Β 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

Β 

None

Β 

Β 

(c) Attachments

Β 

Is a Supplemental Form 8 (Open Positions) attached?

NO

Β 

Β 

Date of disclosure:

16/10/2023

Contact name:

Nancy Dyer

Telephone number:

0207 220 0594

Β 

Β 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

Β 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

Β 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
FEOUNSARORURAAA
Date   Source Headline
1st Jul 20197:21 amEQSHardman & Co Research: Allergy Therapeutics (AGY): Successful legal outcome removes uncertainty
1st Jul 20197:16 amEQSHardman & Co Research: Oxford BioMedica (OXB): Eying up long-term value
27th Jun 20197:00 amRNSSuccessful Litigation Settlement
27th Jun 20197:00 amRNSTrading Statement
19th Jun 20197:00 amRNSBoard Change
11th Jun 20197:00 amRNSHoldings in Company
21st May 20197:15 amEQSHardman & Co Research: Allergy Therapeutics (AGY): House dust mite vaccine - clinical progress
20th May 20197:00 amRNSPositive top line phase I results for Acarovac MPL
14th May 20197:00 amRNSHoldings in Company
13th May 20196:14 pmRNSHolding(s) in Company
13th May 20194:41 pmRNSSecond Price Monitoring Extn
13th May 20194:35 pmRNSPrice Monitoring Extension
7th May 20197:00 amRNSResearch Published on Adjuvant Systems
25th Apr 20197:00 amRNSRegulatory and Trading Update
18th Mar 20194:41 pmRNSSecond Price Monitoring Extn
18th Mar 20194:36 pmRNSPrice Monitoring Extension
18th Mar 201911:30 amEQSHardman & Co Research: Allergy Therapeutics (AGY): Take an objective view
18th Mar 201911:05 amRNSSecond Price Monitoring Extn
18th Mar 201911:00 amRNSPrice Monitoring Extension
18th Mar 20199:05 amRNSSecond Price Monitoring Extn
18th Mar 20199:00 amRNSPrice Monitoring Extension
18th Mar 20197:00 amRNSTop Line Phase III results from B301 trial
6th Mar 201912:10 pmEQSHardman & Co Research: Allergy Therapeutics (AGY): Strong operating performance driving market share
6th Mar 20197:00 amRNSInterim Results
17th Jan 20199:56 amEQSHardman & Co Research: Allergy Therapeutics (AGY): Trading update: gaining market share
16th Jan 20197:00 amRNSTrading Update & Notice of Results
29th Nov 20185:59 pmRNSHoldings in Company
27th Nov 20181:12 pmRNSResult of AGM
27th Nov 20187:00 amRNSAGM Trading Update
12th Nov 201812:00 pmRNSPresentation at Jefferies Healthcare Conference
8th Nov 20187:00 amRNSDirectorate Change
7th Nov 20186:06 pmRNSHoldings in Company
2nd Nov 20187:00 amRNSGrant of Awards under Long Term Incentive Plan
24th Oct 20181:25 pmRNSHoldings in Company
24th Oct 20187:00 amRNSDirector/PDMR Shareholding
23rd Oct 20185:29 pmRNSAnnual Report and Accounts
23rd Oct 20183:28 pmRNSHoldings in Company
27th Sep 20187:15 amEQSHardman & Co Research: Allergy Therapeutics (AGY): 2018 full-year results: solid growth
26th Sep 20187:00 amRNSPreliminary Results
8th Aug 20187:00 amRNSNotice of Results
27th Jul 20185:26 pmRNSHolding(s) in Company
26th Jul 201812:02 pmRNSHolding(s) in Company
19th Jul 201810:19 amRNSResults of Placing and Subscription
19th Jul 20187:00 amRNSProposed placing & subscription to raise £10.6m
16th Jul 20188:53 amRNSBLOCK LISTING SIX MONTHLY RETURN
13th Jul 20189:40 amEQSHardman & Co Research: Allergy Therapeutics (AGY): Steady performance in a tough market
12th Jul 20187:00 amRNSTrading Update
25th Jun 20187:52 amRNSPositive data of Pollinex Quattro Grass vaccine
29th May 20187:00 amRNSPositive data with house-dust mite immunotherapy
21st May 201812:25 pmEQSHardman & Co Research: Allergy Therapeutics (AGY): Opening the door to registration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.